Loading
A phase 1/2 trial of Belantamab mafodotin, Nirogacestat in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM is a phase 1/2 interventional study registered as NCT07084896 by GlaxoSmithKline, with 106 participants enrolled, started 2020-06-08 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
106 enrolled.
95% CI 15.1 to 47.5; Figures from the ClinicalTrials.gov results section (first posted 2026-05-06), not from a publication · 95% CI 22.5 to 55.2
Source95% CI 1.4 to 8.6; Figures from the ClinicalTrials.gov results section (first posted 2026-05-06), not from a publication · 95% CI 4.2 to 20.2
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| CE Phase: Overall Response Rate (ORR)primary | CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat | 34 | 29% | - | - | link |
| CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W | 37 | 38% | ||||
| CE Phase: Progression-free Survival (PFS) | CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat | 34 | 3.5 months | - | - | link |
| CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W | 37 | 9.6 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gamma-secretase inhibitors, Nirogacestat, Belantamab mafodotin, GSK.
Shares Gamma-secretase inhibitors, Nirogacestat, Belantamab mafodotin, GSK.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Nirogacestat, Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/